ArticleScientific reports2025
Exploring the classification and treatment of osteoporosis from the perspectives of natural medicines, molecular targets, and symptom clusters.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bakuchiol Ameliorates Glucocorticoid-Induced Osteoporosis by Enhancing Osteoblast Differentiation via Targeting FAT4 to Activate YAP1.Phytotherapy research : PTR · 2026Article
- Transcriptomics Guided Engineering of Exosome-Encapsulated Bifunctional Nanosheets Targeting the Immune-PI3K/Akt Axis for Osteoporosis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Integrated analysis of Corylin from Psoralea Corylifolia inhibiting osteoporosis via MAPK pathway.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Osteoporosis (OP) is a metabolic bone disease characterized by reduced bone density and fragility, impairing quality of life. Traditional treatments often overlook symptoms like back and joint pain, increasing burden. This study aims to map relationships between natural medicines, targets, and symptom clusters, demonstrating their effectiveness in personalized OP treatment to enhance clinical strategies and self-assessment. We used compounds and targets, applying Summary data-based Mendelian Randomisation (SMR) analysis for biological process and molecular function enrichment. Additionally, we employed Phenome-Wide Association Studies (PheWAS) to select two natural drugs-Rhizoma Drynariae (RD) and Lycii Fructus (LF)-for case analysis. The study found that RD primarily improves symptoms such as indigestion, constipation, fatigue, polyuria, and depression, while LF significantly ameliorates symptoms related to the nervous and muscular systems, such as hoarseness, dizziness, vertigo, and fever symptoms. This analysis successfully differentiated two groups of symptoms and precisely constructed a logical chain among "natural Medicines-molecular tArGets-Illness-symptom Clusters" (MAGIC chain) achieving a refined classification of OP. The results of this study support the effectiveness of implementing personalized medical strategies in the treatment of OP, providing a scientific basis for the clinical application of natural medicines and patient self-management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.